

## PRESS RELEASE

Lyon, December 18, 2025



# ADOCIA Announces its Financial Calendar for 2026

6:00 pm CET- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.

<b>February 24, 2026</b>	Publication of revenue for Q4 2025
<b>April 21, 2026</b>	Publication of 2025 financial statements
<b>May 12, 2026</b>	Publication of revenue for Q1 2026
<b>June 3, 2026</b>	Annual shareholders' meeting
<b>July 23, 2026</b>	Publication of revenue for Q2 2026
<b>September 24, 2026</b>	Publication of mid-year financial statements as of June 30, 2026
<b>October 29, 2026</b>	Publication of revenue for Q3 2026

In addition to regular meetings with the financial community, investors can also find updated information on the company's website ([www.adocia.com](http://www.adocia.com)).

All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company's website, in the Investors' section "[Regulated Information](#)".

# About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong™, a long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

## Contact

### Adocia

**Olivier Soula**

CEO

[contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

+33 (0)4 72 610 610



[www.adocia.com](http://www.adocia.com)

### Ulysse Communication

**Adocia Press & Investor Relations**

Bruno Arabian

Nicolas Entz

[adocia@ulyссе-communication.com](mailto:adocia@ulyссе-communication.com)

+ 33 (0)6 87 88 47 26



European **Rising Tech**  
LABEL



**ADOCIA**

innovative medicine  
for everyone, everywhere

